Are Peptides Safe for Women?

For laboratory and research use only. Not for human consumption.

The Short Answer: Yes, Most Peptides Are Used by Both Men and Women

One of the most common questions we hear is whether peptides are safe for women. The short answer: yes. The vast majority of peptides studied in research are not gender-specific. They work the same way in male and female bodies because they target biological systems that both sexes share — things like gut lining, tissue repair, appetite signaling, and skin cells.

That said, there are some important differences worth knowing about. Some peptides have been studied more in women than in men. A few require different dosing. And there are clear situations — like pregnancy — where peptides should be avoided entirely.

Let’s walk through the major categories.

GLP-1 Peptides: Semaglutide, Tirzepatide, and Retatrutide

The biggest clinical trials for GLP-1 peptides enrolled large numbers of women. In fact, women made up 74% to 81% of participants in the STEP trials for semaglutide. These weren’t small studies — thousands of women participated.

The results? Women actually lost more weight than men on average. In the STEP 1 trial, women in the semaglutide group saw an average weight reduction of 14.0%, compared to 8.0% in men. This pattern held across multiple trials (PMC9981825).

Tirzepatide showed similar results. A post hoc analysis of the SURMOUNT program found that tirzepatide produced significant weight loss in women regardless of reproductive stage — premenopausal, perimenopausal, or postmenopausal (PMC12015656).

Retatrutide, the newest triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, also included women in its phase 2 trials. There is no evidence suggesting it works differently based on sex.

Side Effects in Women

One thing to know: women may report more side effects from GLP-1 peptides than men. A 2024 analysis of adverse event reports found that about 73% of reported side effects from semaglutide came from women (PMC12033487). This could be because more women use these peptides, or because women report side effects more often. Either way, the most common issues — nausea, constipation, and reduced appetite — are the same for both sexes.

BPC-157 and TB-500: No Gender-Specific Concerns

BPC-157 is a peptide fragment derived from a protein found in human stomach juice. It has been studied extensively for tissue repair, gut healing, and reducing inflammation. The vast majority of this research has been done in animal models, and there is no evidence of gender-specific concerns (PMC7096228).

TB-500, a synthetic fragment of thymosin beta-4, is studied for wound healing and tissue repair. Like BPC-157, its mechanism of action — promoting cell migration and new blood vessel formation — is not sex-dependent (PMC8228050).

Both peptides are popular among women in research communities, and neither has shown different effects based on sex in preclinical models.

GHK-Cu: Especially Popular Among Women

GHK-Cu (copper peptide) is one of the most popular peptides among women. It is a naturally occurring tripeptide found in human blood plasma, and its levels decline with age — from about 200 ng/mL at age 20 to just 80 ng/mL by age 60 (PMC4508379).

Research shows GHK-Cu stimulates collagen production, increases skin thickness, improves elasticity, and promotes wound healing. It has also been studied for hair growth, where it appears to work by stimulating hair follicle growth factors and improving blood flow to the scalp (PMC6073405).

There is nothing gender-specific about GHK-Cu’s mechanism. It works on skin cells, collagen, and hair follicles the same way in men and women. Its popularity among women likely comes from the cosmetic research applications — skin quality and hair health — that tend to attract more female interest.

Peptides That Require Extra Caution

While most peptides are fine for both sexes, a few deserve extra attention:

PT-141 (Bremelanotide)

PT-141 acts on melanocortin receptors in the brain. It has been studied for sexual dysfunction in both men and women, but dosing in research protocols often differs between the sexes. Women in clinical studies typically used lower doses. Researchers should be aware of this and consult published protocols before designing experiments.

Growth Hormone Peptides

Peptides like sermorelin and CJC-1295/ipamorelin stimulate your body’s own growth hormone production. They work the same way in both sexes, but women naturally have different growth hormone patterns than men — women tend to produce GH in a more continuous pattern, while men produce it in sharper pulses (PMC2699646).

This doesn’t make these peptides unsafe for women. It just means the hormonal context is slightly different, and researchers should be aware of baseline differences when interpreting results.

Pregnancy and Breastfeeding: A Hard No

This one is simple and non-negotiable: no peptides should be used during pregnancy or breastfeeding.

The reason is straightforward — there is almost no research on peptide safety during pregnancy. Most peptides have never been tested in pregnant women, and animal studies are not sufficient to draw conclusions about human pregnancy safety.

For GLP-1 peptides specifically, manufacturers recommend stopping treatment at least two months before a planned pregnancy. While GLP-1 receptor agonists are large protein molecules unlikely to transfer to breast milk in meaningful amounts, experts advise against using them during breastfeeding due to insufficient human data (PMC11649328).

The same caution applies to BPC-157, TB-500, growth hormone peptides, and every other research peptide. No data means no safety profile, and pregnancy is not the time to experiment.

Fertility Peptides: Actually Designed for Women

Here’s an interesting twist: some peptides are being actively researched specifically for women’s fertility.

Kisspeptin

Kisspeptin is a naturally occurring peptide that plays a critical role in triggering ovulation. It works by stimulating the release of GnRH (gonadotropin-releasing hormone) from the hypothalamus, which in turn triggers the hormones needed for egg maturation.

Kisspeptin-54 is being studied as a safer alternative to hCG (human chorionic gonadotropin) for triggering egg maturation in IVF cycles. It appears to be particularly promising for women at high risk of ovarian hyperstimulation syndrome (OHSS) — a potentially dangerous complication of fertility treatment (PMC4109525).

Research has also found that women with unexplained infertility tend to have lower kisspeptin levels than women with other causes of infertility, suggesting kisspeptin may play a diagnostic role as well (PMC5347457).

Gonadorelin

Gonadorelin is a synthetic version of GnRH. It has been used in fertility research for decades. In IVF protocols, GnRH agonists like gonadorelin can trigger a more natural-feeling surge of LH and FSH — the hormones needed for ovulation — compared to the standard hCG trigger (PMC10767297).

These fertility peptides aren’t just safe for women — they were developed with women’s reproductive health in mind.

Menstrual Cycle Considerations

Some women wonder whether peptides interact with their menstrual cycle. Here’s what the research tells us:

• GLP-1 peptides — There are anecdotal reports of menstrual cycle changes during GLP-1 use, but this likely relates to rapid weight loss (which commonly affects cycles) rather than a direct peptide effect.
• BPC-157 and TB-500 — No known interaction with the menstrual cycle.
• GHK-Cu — No hormonal activity, so no cycle interaction.
• Growth hormone peptides — GH secretion naturally varies across the menstrual cycle, so baseline measurements may differ depending on cycle timing. This is a research design consideration, not a safety concern.

If you notice unexpected changes, it is worth investigating. But most peptides do not directly affect reproductive hormones.

The Bottom Line

Peptides are not a “men’s thing.” The major clinical trials included large numbers of women. Many peptides — like GHK-Cu for skin and hair, or kisspeptin for fertility — are particularly relevant to women’s research interests. The safety profiles, based on available research, do not show meaningful differences between men and women for most peptides.

The key exceptions are simple: avoid all peptides during pregnancy and breastfeeding, be aware of dosing differences for a few specific compounds like PT-141, and remember that rapid weight loss from GLP-1 peptides can temporarily affect menstrual cycles regardless of the peptide itself.

Written by NorthPeptide Research Team

Summary of Key Research References

Topic	Reference	PMC ID
Semaglutide sex-based efficacy differences	Semaglutide in Obesity: Unmet Needs in Men (2023)	PMC9981825
Tirzepatide in women by reproductive stage	Body weight reduction in women treated with tirzepatide (2025)	PMC12015656
Semaglutide adverse events in women	Semaglutide: a gendered phenomenon (2025)	PMC12033487
BPC-157 cytoprotection and safety	BPC 157, Robert’s Stomach Cytoprotection (2020)	PMC7096228
Thymosin beta-4 regenerative properties	Utilizing Developmentally Essential Secreted Peptides (2021)	PMC8228050
GHK-Cu skin regeneration pathways	GHK Peptide as a Natural Modulator in Skin Regeneration (2015)	PMC4508379
GHK-Cu regenerative and protective actions	Regenerative and Protective Actions of GHK-Cu (2018)	PMC6073405
GLP-1 agonists during pregnancy and lactation	GLP-1 receptor agonists during pregnancy and lactation (2024)	PMC11649328
Kisspeptin-54 triggers egg maturation in IVF	Kisspeptin-54 triggers egg maturation in women (2014)	PMC4109525
Kisspeptin and unexplained infertility	Kisspeptin: A Potential Factor for Unexplained Infertility (2017)	PMC5347457
Sermorelin in adult GH insufficiency	Sermorelin: A better approach to adult-onset GH insufficiency (2005)	PMC2699646
GnRH agonist trigger in IVF	GnRH agonist vs HCG for oocyte triggering in ART (2023)	PMC10767297

For laboratory and research use only. Not for human consumption.